Harbor Capital Advisors Inc. Has $1.61 Million Stock Holdings in Cellebrite DI Ltd. (NASDAQ:CLBT)

Harbor Capital Advisors Inc. grew its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 96.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 95,351 shares of the company's stock after purchasing an additional 46,727 shares during the period. Harbor Capital Advisors Inc.'s holdings in Cellebrite DI were worth $1,606,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of CLBT. Janney Montgomery Scott LLC increased its holdings in shares of Cellebrite DI by 8.3% in the 3rd quarter. Janney Montgomery Scott LLC now owns 51,155 shares of the company's stock worth $861,000 after acquiring an additional 3,912 shares during the period. Pembroke Management LTD increased its holdings in shares of Cellebrite DI by 24.3% in the 3rd quarter. Pembroke Management LTD now owns 1,908,345 shares of the company's stock worth $32,137,000 after acquiring an additional 372,619 shares during the period. Meitav Investment House Ltd. increased its holdings in shares of Cellebrite DI by 29.7% in the 3rd quarter. Meitav Investment House Ltd. now owns 2,066,322 shares of the company's stock worth $34,797,000 after acquiring an additional 473,293 shares during the period. Pathway Financial Advisers LLC increased its holdings in shares of Cellebrite DI by 1,583.8% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company's stock worth $74,000 after acquiring an additional 4,118 shares during the period. Finally, Tower View Wealth Management LLC increased its holdings in shares of Cellebrite DI by 1.2% in the 3rd quarter. Tower View Wealth Management LLC now owns 130,647 shares of the company's stock worth $2,200,000 after acquiring an additional 1,500 shares during the period. 45.88% of the stock is owned by institutional investors and hedge funds.

Cellebrite DI Trading Down 0.3 %

Shares of CLBT traded down $0.06 during midday trading on Wednesday, hitting $19.09. The stock had a trading volume of 3,729,482 shares, compared to its average volume of 1,140,828. Cellebrite DI Ltd. has a fifty-two week low of $7.15 and a fifty-two week high of $21.00. The business has a 50-day simple moving average of $17.55 and a two-hundred day simple moving average of $14.20. The firm has a market cap of $3.93 billion, a P/E ratio of -36.02, a price-to-earnings-growth ratio of 2.55 and a beta of 1.50.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 15th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.08 by $0.02. The company had revenue of $95.70 million during the quarter, compared to analysts' expectations of $91.94 million. Cellebrite DI had a negative net margin of 28.51% and a positive return on equity of 5,902.06%. The business's revenue for the quarter was up 24.8% on a year-over-year basis. During the same period last year, the company posted $0.05 earnings per share. On average, analysts expect that Cellebrite DI Ltd. will post 0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Lake Street Capital increased their price objective on shares of Cellebrite DI from $13.50 to $17.00 and gave the stock a "buy" rating in a report on Friday, August 16th. TD Cowen increased their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a "buy" rating in a research report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft increased their target price on shares of Cellebrite DI from $15.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, August 16th. JPMorgan Chase & Co. increased their target price on shares of Cellebrite DI from $14.00 to $15.00 and gave the company an "overweight" rating in a research report on Wednesday, August 14th. Finally, Needham & Company LLC increased their target price on shares of Cellebrite DI from $14.00 to $17.00 and gave the company a "buy" rating in a research report on Friday, August 16th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $18.57.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.